Home/Pipeline/ADCGEN-04

ADCGEN-04

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

CancerAppy

About CancerAppy

CancerAppy is a private, preclinical-stage biotech utilizing an AI-driven platform to accelerate oncology drug discovery. Its pipeline includes a first-in-class ADC targeting a novel antigen (ADCGEN-04), a next-generation TEAD inhibitor (CA09-SM), and a PARP1-specific inhibitor (CA11-SM), all aimed at various solid tumors. The company has secured grant funding from Spanish entities and has signed a pre-licensing agreement for its lead ADC program with an undisclosed U.S. company, positioning it for potential partnerships and pipeline advancement.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed